What is it about?
Meglitinides (Repaglinide, Nateglinide) are useful in the treatment of type 2 diabetes mellitus. These drugs are preferable for the patients having irregular meal timings. The risk of hypoglycemia would be elevated due to most of the drug interactions of meglitinides.
Featured Image
Why is it important?
The drugs inhibiting CYP2C8 enzyme and OATP1B1 transporter can prevent the metabolism and hepatic uptake of Repaglinide and increase it's plasma concentrations leading to enhance risk of Hypoglycemia. The inhibitors of OATP1B1 transporter and CYP2C9 enzyme may interact with Nateglinide and increase it's plasma concentrations and subsequent Hypoglycemia.
Perspectives
I believe the users of Repaglinide and Nateglinide would find this article useful.
Dr Naina Mohamed Pakkir Maideen
Dubai Health Authority
Read the Original
This page is a summary of: Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter, Therapeutic Advances in Endocrinology and Metabolism, April 2018, SAGE Publications,
DOI: 10.1177/2042018818767220.
You can read the full text:
Contributors
The following have contributed to this page
